BI Asset Management Fondsmaeglerselskab A S Acquires Shares of 9,575 Solventum Co. (NYSE:SOLV)

BI Asset Management Fondsmaeglerselskab A S acquired a new stake in shares of Solventum Co. (NYSE:SOLV - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 9,575 shares of the company's stock, valued at approximately $633,000.

Several other large investors also recently added to or reduced their stakes in SOLV. Norges Bank bought a new stake in Solventum in the fourth quarter worth $203,740,000. Boston Partners acquired a new position in shares of Solventum during the 4th quarter valued at about $110,378,000. Independent Franchise Partners LLP raised its stake in shares of Solventum by 105.0% in the 4th quarter. Independent Franchise Partners LLP now owns 1,603,154 shares of the company's stock valued at $105,904,000 after acquiring an additional 821,272 shares in the last quarter. Nordea Investment Management AB lifted its holdings in Solventum by 189.5% in the 4th quarter. Nordea Investment Management AB now owns 659,887 shares of the company's stock worth $43,902,000 after purchasing an additional 431,986 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership boosted its position in Solventum by 41.1% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,193,361 shares of the company's stock worth $78,833,000 after purchasing an additional 347,669 shares during the period.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Wells Fargo & Company boosted their price objective on shares of Solventum from $73.00 to $75.00 and gave the stock an "equal weight" rating in a research note on Friday, February 28th. Piper Sandler boosted their target price on shares of Solventum from $75.00 to $84.00 and gave the stock a "neutral" rating in a research report on Friday, February 28th. Morgan Stanley raised their price target on Solventum from $73.00 to $80.00 and gave the company an "equal weight" rating in a research report on Wednesday, March 5th. Mizuho increased their target price on Solventum from $70.00 to $82.00 and gave the company a "neutral" rating in a research note on Monday, March 3rd. Finally, The Goldman Sachs Group lifted their price target on Solventum from $63.00 to $71.00 and gave the stock a "sell" rating in a research report on Monday, March 3rd. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has assigned a buy rating to the company. According to MarketBeat, the company has an average rating of "Hold" and an average price target of $79.86.

Solventum Stock Performance

SOLV traded down $0.04 on Tuesday, hitting $66.03. 123,234 shares of the stock traded hands, compared to its average volume of 1,295,505. The business has a fifty day moving average price of $72.42 and a two-hundred day moving average price of $71.59. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45. Solventum Co. has a 52 week low of $47.16 and a 52 week high of $85.92. The firm has a market capitalization of $11.42 billion and a PE ratio of 23.99.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.